Harmonization of guidelines for the prevention and treatment of cardiovascular disease: The C-CHANGE Initiative

TY - JOUR

T1 - Harmonization of guidelines for the prevention and treatment of cardiovascular disease

T2 - The C-CHANGE Initiative

AU - Tobe, Sheldon W.

AU - Stone, James A.

AU - Brouwers, Melissa

AU - Bhattacharyya, Onil

AU - Walker, Kimberly M.

AU - Dawes, Martin

AU - Genest, Jacques

AU - Grover, Steven

AU - Gubitz, Gordon

AU - Lau, David

AU - Pipe, Andrew

AU - Selby, Peter

AU - Tremblay, Mark S.

AU - Warburton, Darren E.R.

AU - Ward, Richard

AU - Woo, Vincent

AU - Leiter, Lawrence A.

AU - Liu, Peter P.

N1 - Funding Information: The development of harmonized guidelines was funded entirely from public or government sources. The Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research provided some unrestricted seed funding to start the C-CHANGE harmonization process, through the institute's knowledge translation program. This was complemented by a contribution grant and in-kind support from staff from the Public Health Agency of Canada. Other public or government sources of funding include Cardiac Care Network of Ontario and Ontario Ministry of Health and Long-Term Care. The funders did not have a direct influence on the process or contents of the recommendations or the preparation of the manuscripts. For complete details, see the funding section at the end of the article. Funding Information: Competing interests: Sheldon Tobe has received grants from Baxter, Janssen-Ortho, Novartis, Pfizer, Merck, AstraZeneca and Amgen; consulting fees or honoraria, or payment for lectures or educational presentations, from Pfizer, Bristol-Myers Squibb–Sanofi-aventis, Merck and Abbott; and support for travel to meetings for the study or other purposes from Bristol-Myers Squibb–Sanofi-aventis, Merck, Pfizer, AstraZeneca, Abbott and Boehringer Ingelheim. James Stone has received consulting fees and payment for lectures or development of educational presentations from AstraZeneca, Merck, Novartis, Pfizer and Servier; payment for manuscript preparation from the Cardio-Metabolic Research Group. His institution has received grants or has grants pending from the Canadian Institutes of Health Research. None declared by Melissa Brouwers. Onil Bhattacharyya has received funds through an Ontario Ministry of Health and Long-Term Care Career Scientist Award. None declared by Kimberly Walker. Martin Dawes has received funds from Health Canada for travel. Jacques Genest Jr. has received consulting fees or honoraria, or payment for development of educational presentations from Amgen, Merck, AstraZeneca and Pfizer. Steven Grover has received funds as a board member of or consulting fees for Merck, Pfizer and AstraZeneca; has provided expert testimony for Otsuka; and has grants or grants pending from Otsuka and Merck. Gordon Gubitz has received payment for lectures from Boehringer Ingelheim and Sanofi. David Lau has received consulting fees or speaker's honoraria, payment for lectures or has grants or grants pending from Abbott, Allergan, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Pfizer and Sanofi-aventis. He has received payment from AstraZeneca for development of lipid education programs. He has given expert testimony or reports to the Canadian Medical Protective Association. Andrew Pipe has received funds as a board member for Pfizer, Johnson & Johnson and GlaxoSmithKline; fees for educational presentations from Pfizer and Johnson & Johnson; payment for manuscript preparation from Snell Publications and Parkhurst Exchange; payment for development of educational materials for Pfizer; and honoraria from a variety of government and voluntary health organizations, hospitals and medical organizations for the preparation of reports and the development and delivery of educational presentations. Peter Selby has received funds as a board member for or consulting fees from Schering Canada, Johnson & Johnson, Consumer Healthcare Canada, Pfizer, Sanofi-Synthelabo Canada, GlaxoSmithKline, Genpharm, Prempharm, Nabi Bioharmaceuticals, V-CC Systems, Inc. and eHealth Behaviour Change Software Co. He has received payment for lectures or development of educational presentations from Pfizer and Johnson & Johnson. His institution has grants or grants pending from Centre for Addiction and Mental Health; Ontario Ministry of Health Promotion; Tobacco Control Program, Health Canada; National Institute on Drug Abuse; Cancer Care Ontario; Pfizer; Canadian Tobacco Control Research Initiative; Canadian Institutes for Health Research; Vancouver Coastal Health; and Alberta Health Services (formerly Alberta Cancer Board). Mark Tremblay has been paid by various entities to give keynote addresses related to physical activity (see Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.101508/-/DC1 , for a list of the entities). None declared by Darren Warburton. Richard Ward has received consulting fees, payment for lectures or payment for development of educational presentations from Pfizer, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Sanofi-aventis. Vincent Woo has received consulting fees or honoraria, or payment for lectures from AstraZeneca, Bristol-Myers Squibb, Abbott, Novo Nordisk, Eli Lilly, Sanofi-aventis, Boehringer Ingelheim and Merck. Lawrence Leiter has received consulting fees or honoraria, or has grants or grants pending from AstraZeneca, Merck, Pfizer, Roche, Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Novartis, Novo Nordisk, Sanofi-aventis and Servier. Peter Liu has grants or grants pending from Pfizer, Servier and Novartis. He was director of the Institute of Circulatory and Respiratory Health at CIHR at the beginning of the project, but most of the manuscript writing was done following completion of his term at CIHR. Conflict of Interest Management and Central Review Committee: To address conflicts of interest, each member of the C-CHANGE Guideline Panel declared all sources of funding and all real or potential conflicts of interest. This approach has allowed the development of a plan that has ensured competing interests were managed at every level of the program. The Central Review Committee is composed of methodologic experts who are free from all conflicts of interest, who can ensure the evidence is critically appraised and graded consistently. Funding Information: Funding: The development of harmonized guidelines was funded entirely from public or government sources. The Institute of Circulatory and Respiratory Health (ICRH) at the CIHR provided some unrestricted seed funding to start the C-CHANGE harmonization process, through the institute's knowledge translation program. This was complemented by a contribution grant and in-kind support from staff from the Public Health Agency of Canada. The support from ICRH and the Public Health Agency of Canada was part of their commitment to the federal government's Canadian Heart Health Strategy recommendation. Other public or government sources of funding include Cardiac Care Network of Ontario and Ontario Ministry of Health and Long-Term Care. The following grants were associated with this project: Ministry of Health and Long-Term Care Alternative Funding Plans Innovation Grant and Public Health Agency of Canada no. 6282-15-2010/3381084 . The funders did not have a direct influence on the process or contents of the recommendations or the preparation of the manuscripts. Peter Liu, the former scientific director of ICRH, did not participate in the manuscript writing until the completion of his term at ICRH. Guidelines

PY - 2011/10/18

Y1 - 2011/10/18

UR - http://www.scopus.com/inward/record.url?scp=80054715975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054715975&partnerID=8YFLogxK

U2 - 10.1503/cmaj.101508

DO - 10.1503/cmaj.101508

M3 - Article

AN - SCOPUS:80054715975

SN - 0820-3946

VL - 183

SP - E1135-E1150

JO - CMAJ

JF - CMAJ

IS - 15

ER -